Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + FOLFOXIRI + Bevacizumab in MSS Colorectal Cancer
NCT05839470Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2023
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in colorectal cancer (CRC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05839470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839470.